Back to Search
THERESA CASSANO, DMD
DMD
Dentist
NPI: 1972779064Individual
Specialties, Licenses & Credentials
DentistPrimary
Dentist
Code: 122300000X
22DIO2086200(NJ)
Research & Publications (20)
Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.
PMID 19607756·Int J Neuropsychopharmacol·2010
7-preclinical
Short- and long-term consequences of prenatal exposure to the cannabinoid agonist WIN55,212-2 on rat glutamate transmission and cognitive functions.
PMID 19533296·J Neural Transm (Vienna)·2009
6-review
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
PMID 19607961·Int Rev Neurobiol·2009
7-preclinical
Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2.
PMID 19010365·Neurochem Int·2009
7-preclinical
Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion.
PMID 19229609·Neurochem Res·2009
7-preclinical
Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats.
PMID 18452035·Psychopharmacology (Berl)·2008
7-preclinical
Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model.
PMID 18335518·J Neurosci Res·2008
7-preclinical
Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated with alteration of cortical gene expression and neurotransmission in rats.
PMID 17578508·Addict Biol·2007
7-preclinical
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.
PMID 17900568·Exp Neurol·2007
7-preclinical
Neurochemical and neurobehavioral effects of ganstigmine (CHF2819), a novel acetylcholinesterase inhibitor, in rat prefrontal cortex: an in vivo study.
PMID 17822918·Pharmacol Res·2007
7-preclinical
Prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 increases glutamate uptake through overexpression of GLT1 and EAAC1 glutamate transporter subtypes in rat frontal cerebral cortex.
PMID 17631920·Neuropharmacology·2007
7-preclinical
Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function.
PMID 16950604·Eur Neuropsychopharmacol·2007
4-observational
Preliminary results of oxygen saturation with a prototype of continuous wave laser oximeter.
PMID 16927670·Adv Exp Med Biol·2006
8-other
Prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 and carbon monoxide reduces extracellular glutamate levels in primary rat cerebral cortex cell cultures.
PMID 16777266·Neurochem Int·2006
7-preclinical
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.
PMID 16352709·Proc Natl Acad Sci U S A·2005
7-preclinical
Investigation of the excited-state absorption of a Ru dioxolene complex by the Z-scan technique.
PMID 15945645·J Chem Phys·2005
8-other
Prenatal exposure to the CB1 receptor agonist WIN 55,212-2 causes learning disruption associated with impaired cortical NMDA receptor function and emotional reactivity changes in rat offspring.
PMID 15788701·Cereb Cortex·2005
7-preclinical
The effects of nitric oxide on striatal serotoninergic transmission involve multiple targets: an in vivo microdialysis study in the awake rat.
PMID 15145769·Brain Res·2004
7-preclinical
Antinutritional effects of fumonisin B1 and pathophysiological consequences.
PMID 12676494·Toxicol Lett·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 168 MOUNTAIN AVE
HACKETTSTOWN, NJ 07840 - Phone
- (908) 852-6611
Quick Facts
- NPI
- 1972779064
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile